Immunocore

Yahoo Finance • 9 days ago

Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference

Immunocore Holdings plc Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 06 April 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or... Full story

Yahoo Finance • 20 days ago

Jefferies Downgrades Immunocore Holdings plc (IMCR) to Hold with a $33 Price Target

Immunocore Holdings plc (NASDAQ:IMCR) is one of the 12 Best UK Stocks to Buy According to Hedge Funds. On March 16, 2026, Jefferies downgraded Immunocore Holdings plc (NASDAQ:IMCR) to Hold from Buy previously with a price target of $33, d... Full story

Yahoo Finance • 28 days ago

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting (OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn., US, 17 March 2026) Immunocore Holdings plc (Nasdaq: IMCR) (... Full story

Yahoo Finance • 30 days ago

Qualcomm, Adobe downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Clear Street upgraded Circle Internet(... Full story

Yahoo Finance • 30 days ago

Here Are Monday’s Top Wall Street Analyst Research Calls: Alnylam Pharmaceuticals, Circle Internet, Fifth Third Bancorp, Intuit, ServiceNow, Qualcomm, Trade Desk, and More

Quick Read Stocks closed lower once again on Friday, handing investors their third consecutive week of losses. The “Buy the Dip” investors were rarely wrong using that tactic over the last 3 years, but have been scorched recently While it... Full story

Yahoo Finance • last month

Immunocore to present at upcoming investor conferences

Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 03 March 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology... Full story

Yahoo Finance • 5 months ago

Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting

Single ascending dose data show IMC-I109V has manageable safety profile and antiviral activity IMC-I109V is a bispecific T cell receptor targeting a peptide derived from HBsAg that is presented by HLA-A*02:01 on the surface of infected he... Full story

Yahoo Finance • 5 months ago

Immunocore reports third quarter financial results and provides a business update

Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $103.7 million in 3Q 2025, growing by 29% year-over-year Phase 3 TEBE-AM trial on track to complete enrollment... Full story

Yahoo Finance • 8 months ago

Jefferies assumes coverage on Immunocore stock with Buy rating, $48 target

Investing.com - Jefferies has assumed coverage on Immunocore Holdings (NASDAQ:IMCR) with a Buy rating and a $48.00 price target, according to a research note released Monday. The company, currently trading at $32.93, shows strong financial... Full story

Yahoo Finance • 8 months ago

Immunocore Holdings PLC (NASDAQ:IMCR) Beats Q2 2025 Revenue and EPS Estimates with Strong KIMMTRAK Sales Growth

Immunocore Holdings PLC (NASDAQ:IMCR [https://www.chartmill.com/stock/quote/IMCR]) reported its second-quarter 2025 financial results, delivering revenue and earnings per share (EPS) figures that exceeded analyst expectations. The company... Full story

Yahoo Finance • 8 months ago

Immunocore reports second quarter financial results and provides a business update

KIMMTRAK® (tebentafusp-tebn) net revenues of $98.0 million in Q2 2025, growing by 30% year-over-year Phase 3 TEBE-AM trial on track to complete enrollment in 1H 2026 Dose selection for PRISM-MEL-301 Phase 3 trial expected in 2H 2025 Pha... Full story

Yahoo Finance • 8 months ago

Immunocore to report second quarter 2025 financial results and host call on August 7, 2025

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, July 31, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative i... Full story

Yahoo Finance • 9 months ago

Immunocore stock price target raised to $36 from $33 at Mizuho

Investing.com - Mizuho has raised its price target on Immunocore Holdings (NASDAQ:IMCR) to $36.00 from $33.00 while maintaining a Neutral rating on the stock. According to InvestingPro data, the company maintains a "GREAT" financial health... Full story

Yahoo Finance • 10 months ago

Immunocore's SWOT analysis: stock outlook amid pipeline progress, market challenges

Immunocore Holdings plc (NASDAQ:IMCR), a biotechnology company specializing in T-cell receptor-based therapeutics for cancer and infectious diseases, has been navigating a complex landscape of clinical advancements and market challenges. W... Full story

Yahoo Finance • last year

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 IMC-M113V was well tolerated, with no dose-limiting toxicities Signals of dose-dependent reduction in active... Full story

Yahoo Finance • last year

Immunocore reports fourth quarter and full year 2024 financial results and provides a business update

KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025 Executing on KIMMTRAK lifecycle management with two Phase 3 trials (TEBE-AM and ATOM) in additional melanoma ind... Full story

Yahoo Finance • 2 years ago

Immunocore Holdings plc (IMCR): Worst 52-Week Low Stock to Buy Now

We recently compiled a list of the 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers.In this article, we are going to take a look at where Immunocore Holdings plc (NASDAQ:IMCR) stands against the other Worst 52-Week Low Sto... Full story

Yahoo Finance • 2 years ago

Immunocore Holdings plc (IMCR) Hits 52-Week Low Despite 34% Surge in KIMMTRAK Sales

We recently published a list of 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers. In this article, we are going to take a look at where Immunocore Holdings plc (NASDAQ:IMCR) stands against the other worst 52-week low stock... Full story

Yahoo Finance • 2 years ago

Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma

Immunocore Holdings plc Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma The Phase 3 PR... Full story

Yahoo Finance • 2 years ago

An Intrinsic Calculation For Immunocore Holdings plc (NASDAQ:IMCR) Suggests It's 50% Undervalued

Key Insights The projected fair value for Immunocore Holdings is US$136 based on 2 Stage Free Cash Flow to Equity Immunocore Holdings is estimated to be 50% undervalued based on current share price of US$68.32 Analyst price target for IMC... Full story